0001415889-23-001587.txt : 20230130
0001415889-23-001587.hdr.sgml : 20230130
20230130164507
ACCESSION NUMBER: 0001415889-23-001587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Braunstein Scott
CENTRAL INDEX KEY: 0001643875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36576
FILM NUMBER: 23568482
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 3891 RANCHERO DRIVE, SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001267813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-801-4670
MAIL ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
FORMER COMPANY:
FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031022
4
1
form4-01302023_090159.xml
X0306
4
2023-01-26
0001267813
MARINUS PHARMACEUTICALS, INC.
MRNS
0001643875
Braunstein Scott
5 RADNOR CORPORATE CENTER, SUITE 500
100 MATSONFORD RD
RADNOR
PA
19087
true
true
false
false
CHAIRMAN AND CEO
Common Stock
2023-01-26
4
A
0
80000
0
A
167205
D
Stock Option (Right to Buy)
5.94
2023-01-26
4
A
0
360000
0
A
2033-01-26
Common Stock
360000
360000
D
Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2024, the second installment vesting on February 15, 2025, and the third installment vesting on February 15, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer.
/s/ Debra A. Mohollen, Attorney-in-Fact
2023-01-30